Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in ...
October 05 2018 - 9:10AM
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced
that results of its Phase 2 clinical trial studying AG10 in
subjects with symptomatic transthyretin (TTR) amyloidosis
cardiomyopathy (ATTR-CM) will be announced in a late-breaking
featured science oral presentation at this year’s American Heart
Association (AHA) Scientific Sessions.
Daniel Judge, M.D., professor in the division of cardiology at
the Medical University of South Carolina, will discuss the data in
a presentation entitled “Safety, Tolerability and Transthyretin
Stabilization by AG10: A Phase 2, Randomized, Double-blind,
Placebo-controlled Clinical Trial in Patients with Transthyretin
Amyloid Cardiomyopathy and NYHA Class II/III Heart Failure” as
part of the New Trials in Cardiovascular Care oral session at 9:00
AM CT on November 10, 2018.
Eidos will host an investor conference call and webcast
following the presentation to highlight details of the Phase 2
data. Details for the call and webcast will be announced at a later
date.
About AG10
AG10 is an investigational, orally-administered small molecule
designed to potently stabilize tetrameric transthyretin, or TTR,
thereby halting at its outset the series of molecular events that
give rise to amyloidosis, or ATTR. AG10 is currently being examined
in an open-label extension of a Phase 2 clinical trial in patients
with ATTR cardiomyopathy.
AG10 was designed to mimic a naturally-occurring variant of the
TTR gene (T119M) that is considered a “rescue mutation” because it
has been shown to prevent ATTR in individuals carrying pathogenic,
or disease-causing, mutations in the TTR gene. To our knowledge,
AG10 is the only TTR stabilizer in development that has been
observed to mimic the “super-stabilizing” properties of this rescue
mutation.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company
focused on addressing the large and growing unmet need in diseases
caused by transthyretin (TTR) amyloidosis (ATTR). For more
information, please visit www.eidostx.com.
Media Contact:Carolyn HawleyCanale
Communications619-849-5382Carolyn@canalecomm.com
Investor Contact:Alex GrayBurns
McClellan212-213-0006agray@burnsmc.com
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Sep 2023 to Sep 2024